Metagenomi
Metagenomi is a genetic medicines company that discovers and develops next-generation CRISPR gene editing systems derived from metagenomics. The company uses metagenomics—the study of genetic material recovered from natural environments—to unlock four billion years of microbial evolution and discover novel editing tools. The company's comprehensive genome editing toolbox includes programmable nucleases, base editors, prime editing systems, and CRISPR-associated transposases (CASTs). Metagenomi develops in vivo and ex vivo gene editing therapeutics for genetic diseases and oncology.
Public Company
Metagenomi is publicly traded
IPO'd on February 13, 2024
This company is no longer available on our private secondary market. Shares can be traded publicly under MGX.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2016
Employees
100–150
Total Funding
$443.75M
5 rounds
Last Private Valuation
$0.2B
January 10, 2023
Funding
Total raised $443.75M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series B Extension
Date
January 10, 2023
Amount
$100M
Valuation
$0.2B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| February 9, 2024 | IPO | $93.75M | — | Public offering |
| January 10, 2023 | Series B Extension | $100M | $0.2B | Novo Holdings |
| February 22, 2022 | Series B | $175M | — | PFM Health Sciences, Farallon Capital, undisclosed third firm |
Prominent Investors
Leadership
Brian C. Thomas
Chief Executive Officer and Founder
Jillian Banfield
Co-Founder and Scientific Advisor
Sebastian Bernales
Co-Founder
Luis Borges
Chief Scientific Officer
Alan Brooks
Senior Vice President, Preclinical
Christopher T. Brown
Vice President, Discovery
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Editas Medicine
CRISPR gene editing pioneer with approved and clinical-stage assets in development for genetic diseases and oncology.
BEAM Therapeutics
Leading base editing company developing therapeutics through precision base conversion rather than double-stranded breaks.
Intellia Therapeutics
Clinical-stage CRISPR therapeutics company advancing in vivo genome editing for genetic diseases.
CRISPR Therapeutics AG
Pioneer in CRISPR gene editing with approved therapies and clinical pipeline for genetic blood diseases.
Caribou Biosciences
Off-the-shelf CAR-T cell therapy company using proprietary genome editing technology to enhance immunotherapy.
Sangamo Therapeutics
Gene editing company developing in vivo and ex vivo therapeutics using zinc finger proteins and genome editing technologies.
Metagenomi Investment FAQ
Metagenomi FAQ
Yes, Metagenomi is publicly traded under the ticker symbol MGX on the NASDAQ. The company went public in February 13, 2024.
Metagenomi trades under the ticker symbol MGX on the NASDAQ. It began trading in February 13, 2024.
Metagenomi (MGX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker MGX to place an order.
Metagenomi went public in February 13, 2024 via ipo, with an offering valuation of approximately $0.2B. Metagenomi completed its initial public offering on February 13, 2024, with 6,250,000 shares priced at $15.00 per share, raising $93.75 million gross proceeds. The company's common stock trades on the Nasdaq Global Select Market under the ticker symbol MGX. The IPO followed successful Series B funding rounds totaling $275 million and positioned the company to advance its lead in vivo and ex vivo gene editing therapeutic programs toward clinical development.
Metagenomi raised $443.75M across 5 disclosed funding rounds prior to its public listing.
Metagenomi was co-founded by Brian C. Thomas, Jillian Banfield, and Sebastian Bernales in 2016.
Metagenomi is headquartered in Emeryville, CA, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.